Opinion|Videos|October 18, 2024
Challenging Adverse Events with GPRC5D-Targeted Therapies
Panelists discuss how cytokine release syndrome and neurological toxicities have been the most challenging adverse events to manage with GPRC5D-targeted therapies, requiring proactive monitoring and intervention strategies, while noting that these side effects are generally similar to those seen with other bispecifics.
Advertisement
Episodes in this series
- What adverse events have been most challenging to manage with GPRC5D-targeted therapies?
- How are these being managed?
- Do the AEs differ from other bispecifics?
- In what ways could the availability of GPRC5D-targeted therapies impact the broader therapeutic landscape for RRMM in community practices?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
4
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
5